EA201071248A1 - Дизамещенные фталазиновые антагонисты пути hedgehog - Google Patents

Дизамещенные фталазиновые антагонисты пути hedgehog

Info

Publication number
EA201071248A1
EA201071248A1 EA201071248A EA201071248A EA201071248A1 EA 201071248 A1 EA201071248 A1 EA 201071248A1 EA 201071248 A EA201071248 A EA 201071248A EA 201071248 A EA201071248 A EA 201071248A EA 201071248 A1 EA201071248 A1 EA 201071248A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antagonists
phthalasine
hedgehog
ways
designed
Prior art date
Application number
EA201071248A
Other languages
English (en)
Russian (ru)
Inventor
Филип Артур Хипскинд
Такако Уилсон
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201071248A1 publication Critical patent/EA201071248A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA201071248A 2008-04-29 2009-04-01 Дизамещенные фталазиновые антагонисты пути hedgehog EA201071248A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4872908P 2008-04-29 2008-04-29
PCT/US2009/039065 WO2009134574A2 (en) 2008-04-29 2009-04-01 Disubstituted phthalazine hedgehog pathway antagonists

Publications (1)

Publication Number Publication Date
EA201071248A1 true EA201071248A1 (ru) 2011-06-30

Family

ID=40846962

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071248A EA201071248A1 (ru) 2008-04-29 2009-04-01 Дизамещенные фталазиновые антагонисты пути hedgehog

Country Status (22)

Country Link
US (1) US7981892B2 (enExample)
EP (1) EP2294061A2 (enExample)
JP (1) JP5442717B2 (enExample)
KR (1) KR101260116B1 (enExample)
CN (1) CN102066353B (enExample)
AU (1) AU2009241561B2 (enExample)
BR (1) BRPI0911618A2 (enExample)
CA (1) CA2723042A1 (enExample)
CO (1) CO6300945A2 (enExample)
CR (1) CR11741A (enExample)
DO (1) DOP2010000302A (enExample)
EA (1) EA201071248A1 (enExample)
EC (1) ECSP10010577A (enExample)
HN (1) HN2010002157A (enExample)
IL (1) IL208211A0 (enExample)
MA (1) MA32349B1 (enExample)
MX (1) MX2010011948A (enExample)
MY (1) MY159491A (enExample)
NZ (1) NZ588001A (enExample)
UA (1) UA102250C2 (enExample)
WO (1) WO2009134574A2 (enExample)
ZA (1) ZA201006695B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102066353B (zh) 2008-04-29 2013-12-11 伊莱利利公司 二取代的酞嗪Hedgehog通路拮抗剂
ES2418479T3 (es) 2008-11-03 2013-08-14 Eli Lilly And Company Antagonistas de la ruta erizo de ftalazinas disustituidas
MX2011005177A (es) 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
JP5518088B2 (ja) 2008-11-17 2014-06-11 イーライ リリー アンド カンパニー 四置換ピリダジンヘッジホッグ経路アンタゴニスト
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
JP2013511526A (ja) * 2009-11-18 2013-04-04 ノバルティス アーゲー 固形腫瘍及びその他の悪性腫瘍を治療するための方法及び組成物
CN102702108A (zh) * 2012-06-27 2012-10-03 上海大学 1,2-二氢酞嗪类化合物及其合成方法
CA2878082A1 (en) * 2012-09-17 2014-03-20 Duke University Smoothened modulators and methods of use thereof
CN102863393A (zh) * 2012-09-26 2013-01-09 上海大学 1,2-二氢酞嗪类化合物及其合成方法
GB201309508D0 (en) 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
CN107163028B (zh) * 2017-05-24 2019-07-12 东南大学 一种苯甲酰胺类Hedgehog抑制剂及其制备方法和应用
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
JP7868066B2 (ja) 2020-10-13 2026-06-01 エンデバー バイオメディシンズ， インコーポレイテッド 線維症を処置する方法
CN119907797A (zh) * 2022-09-23 2025-04-29 默沙东有限责任公司 用作nod样受体蛋白3抑制剂的酞嗪衍生物
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
AU717744B2 (en) 1996-01-15 2000-03-30 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
US6432970B2 (en) * 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
JP5067986B2 (ja) 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
GB0013674D0 (en) 1999-06-08 2000-07-26 Lorantis Ltd Therapeutic use
AU2003231032B2 (en) 2002-04-22 2008-07-10 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
EP1745039A4 (en) 2004-05-08 2009-07-22 Neurogen Corp 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES
WO2006028958A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
US8536168B2 (en) * 2007-03-15 2013-09-17 Novartis Ag Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway
US8153633B2 (en) * 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
AU2008300019A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
CN102066353B (zh) 2008-04-29 2013-12-11 伊莱利利公司 二取代的酞嗪Hedgehog通路拮抗剂
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
ES2418479T3 (es) 2008-11-03 2013-08-14 Eli Lilly And Company Antagonistas de la ruta erizo de ftalazinas disustituidas
MX2011005177A (es) 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
JP5518088B2 (ja) 2008-11-17 2014-06-11 イーライ リリー アンド カンパニー 四置換ピリダジンヘッジホッグ経路アンタゴニスト
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Also Published As

Publication number Publication date
AU2009241561A1 (en) 2009-11-05
US20110046143A1 (en) 2011-02-24
KR101260116B1 (ko) 2013-05-02
CR11741A (es) 2011-01-05
WO2009134574A2 (en) 2009-11-05
BRPI0911618A2 (pt) 2019-09-24
JP5442717B2 (ja) 2014-03-12
MA32349B1 (fr) 2011-06-01
ZA201006695B (en) 2012-09-26
KR20100126580A (ko) 2010-12-01
HN2010002157A (es) 2014-09-08
AU2009241561B2 (en) 2013-05-16
CO6300945A2 (es) 2011-07-21
MX2010011948A (es) 2010-12-14
MY159491A (en) 2017-01-13
CA2723042A1 (en) 2009-11-05
WO2009134574A3 (en) 2014-09-04
CN102066353B (zh) 2013-12-11
ECSP10010577A (es) 2010-11-30
NZ588001A (en) 2012-06-29
US7981892B2 (en) 2011-07-19
UA102250C2 (ru) 2013-06-25
DOP2010000302A (es) 2010-11-15
JP2011527666A (ja) 2011-11-04
CN102066353A (zh) 2011-05-18
IL208211A0 (en) 2010-12-30
EP2294061A2 (en) 2011-03-16

Similar Documents

Publication Publication Date Title
JO2931B1 (en) Double-substituted phthalazin compounds as antagonists of the cell-specific factor pathway
MY159491A (en) Disubstituted phthalazine hedgehog pathway antagonists
TN2011000166A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA201171367A1 (ru) Винилиндазолильные соединения
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
MX338884B (es) Composiciones y metodos que comprenden variantes de proteasa.
CR20120202A (es) Métodos y composiciones para tratar cáncer
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
CL2010001474A1 (es) Compuestos derivados de tiofeno o tiazol sustituidos, inhibidores de pi3k; composicion farmaceutica; utiles en el tratamiento del cancer, inflamacion y en el tratamiento de trastornos cardiovasculares.
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
CL2015003595A1 (es) Inhibidores/antiandrógenos novedosos de cyp17
EA201170699A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
NO20093542L (no) Inhibering av tumormetastase ved hjelp av anti-neuropilin 2-antistoffer
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
MX2009012767A (es) Metodos de tratamiento de infecciones fungicas.
EA201170700A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
MA32321B1 (fr) Pregn-4-en-21, 17 carbolactones substitués sur le noyau c, et préparations pharmaceutiques contenant ces derniers
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
DK2155179T3 (da) Axomadol til smertebehandling arthrose
TN2010000489A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
CY1114078T1 (el) Ανταγωνιστες διυποκατεστημενης φθαλαζινης του μονοπατιου hedgehog